Receptor Tyrosine Kinase-Targeted Cancer Therapy

@inproceedings{Yamaoka2018ReceptorTK,
  title={Receptor Tyrosine Kinase-Targeted Cancer Therapy},
  author={Toshimitsu Yamaoka and Sojiro Kusumoto and Kōichi Andō and Masahiro Ohba and Tohru Ohmori},
  booktitle={International journal of molecular sciences},
  year={2018}
}
In the past two decades, several molecular targeted inhibitors have been developed and evaluated clinically to improve the survival of patients with cancer. Molecular targeted inhibitors inhibit the activities of pathogenic tyrosine kinases. Particularly, aberrant receptor tyrosine kinase (RTK) activation is a potential therapeutic target. An increased understanding of genetics, cellular biology and structural biology has led to the development of numerous important therapeutics. Pathogenic RTK… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 254 REFERENCES

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

  • The New England journal of medicine
  • 2017
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

  • The New England journal of medicine
  • 2013
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

  • The New England journal of medicine
  • 2017
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

G. D. Demetri, M. von Mehren, +7 authors M Janicek
  • N. Engl. J. Med
  • 2002
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Mechanisms of resistance to egfr-targeted drugs: Lung cancer

F. Morgillo, C. M. Della Corte, M. Fasano, F. Ciardiello
  • ESMO Open 2016,
  • 2016
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL